
ESLA Stock Forecast & Price Target
ESLA Analyst Ratings
Bulls say
Estrella Immunopharma is advancing its EB104 dual CD19/CD22 program, which has shown promising results, including a favorable safety profile and a complete response in one patient, indicating the potential efficacy of its therapies in treating B-cell malignancies and autoimmune indications. The company's strategic move into a higher dose cohort strengthens its position within the evolving T-cell therapy market and enhances its development prospects. Furthermore, the innovative Artemis Technology platform may unlock new market opportunities in immunology and solid tumor treatments, reinforcing the positive outlook on Estrella's long-term growth potential in the biopharmaceutical sector.
Bears say
The financial outlook for Estrella Immunopharma appears negative due to the lack of substantial revenue generation from its current clinical-stage pipeline, which is still in the early phases of development for addressing B-cell Non-Hodgkin’s Lymphomas. Additionally, the repetitive financial data presented for the target market in China indicates a more speculative growth potential rather than immediate financial viability, as it highlights an absence of current cash flow from approved products. Furthermore, without confirmed clinical success and regulatory approvals, the company's ability to capture a portion of the estimated market growth and translate it into meaningful financial performance remains uncertain.
This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
ESLA Analyst Forecast & Price Prediction
Start investing in ESLA
Order type
Buy in
Order amount
Est. shares
0 shares